These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27482428)

  • 1. HIV-1 prophylactic vaccines: state of the art.
    Lelièvre JD; Lévy Y
    J Virus Erad; 2016 Jan; 2(1):5-11. PubMed ID: 27482428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV Vaccine Efficacy Trials: RV144 and Beyond.
    Heger E; Schuetz A; Vasan S
    Adv Exp Med Biol; 2018; 1075():3-30. PubMed ID: 30030787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection.
    Kim JH; Excler JL; Michael NL
    Annu Rev Med; 2015; 66():423-37. PubMed ID: 25341006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review.
    Girard MP; Osmanov S; Assossou OM; Kieny MP
    Vaccine; 2011 Aug; 29(37):6191-218. PubMed ID: 21718747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.
    Perez LG; Martinez DR; deCamp AC; Pinter A; Berman PW; Francis D; Sinangil F; Lee C; Greene K; Gao H; Nitayaphan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Tartaglia J; O'Connell RJ; Robb ML; Michael NL; Kim JH; Gilbert P; Montefiori DC
    PLoS One; 2017; 12(7):e0180720. PubMed ID: 28678869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
    Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a cytomegalovirus vaccine: lessons from recent clinical trials.
    Gonczol E; Plotkin S
    Expert Opin Biol Ther; 2001 May; 1(3):401-12. PubMed ID: 11727514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccines and vaccine strategies against HIV.
    Stratov I; DeRose R; Purcell DF; Kent SJ
    Curr Drug Targets; 2004 Jan; 5(1):71-88. PubMed ID: 14738219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects for a globally effective HIV-1 vaccine.
    Excler JL; Robb ML; Kim JH
    Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
    Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
    J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune correlates of vaccine protection against HIV-1 acquisition.
    Corey L; Gilbert PB; Tomaras GD; Haynes BF; Pantaleo G; Fauci AS
    Sci Transl Med; 2015 Oct; 7(310):310rv7. PubMed ID: 26491081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 prophylactic vaccine trials in Thailand.
    Pitisuttithum P
    Curr HIV Res; 2005 Jan; 3(1):17-30. PubMed ID: 15638720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
    McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for a Globally Effective HIV-1 Vaccine.
    Excler JL; Robb ML; Kim JH
    Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S307-18. PubMed ID: 26590431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent update in HIV vaccine development.
    Shin SY
    Clin Exp Vaccine Res; 2016 Jan; 5(1):6-11. PubMed ID: 26866018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
    Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
    J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in HIV vaccine development.
    Hsu DC; O'Connell RJ
    Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.